Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution

Human Gene Therapy

Volumn 15, Issue 12, 2004, Pages 1255-1269

  Konstan, Michael W ^a   Davis, Pamela B ^a   Wagener, Jeffrey S ^b   Hilliard, Kathleen A ^a   Stern, Robert C ^a   Milgram, Laura J H ^a   Kowalczyk, Tomasz H ^c   Hyatt, Susannah L ^c   Fink, Tamara L ^c   Gedeon, Christopher R ^c   Oette, Sharon M ^c   Payne, Jennifer M ^c   Muhammad, Osman ^c   Ziady, Assem G ^a   Moen, Robert C ^c   Cooper, Mark J ^c,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Copernicus Therapeutics ^*  (United States)

^d Copernicus Therapeutics Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; ISOPRENALINE; LYSINE; MACROGOL; NANOPARTICLE; PEPTIDE; PLASMID DNA;

ADULT; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; GENE TRANSFER; HEARING TEST; HUMAN; INFLAMMATION; LABORATORY TEST; LUNG FUNCTION; MALE; NOSE MUCOSA; POLYMERASE CHAIN REACTION; SAFETY;

EID: 19944398726     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2004.15.1255     Document Type: Article

References (80)

1. AITKEN, M.L., MOSS, R.B., WALTZ, D.A., DOVEY, M.E., TONELLI, M.R., McNAMARA, S.C., GIBSON, R.L., RAMSEY, B.W., CARTER, B.J., and REYNOLDS, T.C. (2001). A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Then 12, 1907-1916.
2. ALTON, E.W.F.W., STERN, M., FARLEY, R., JAFFEE, A., CHADWICK, S.L., PHILLIPS, J., DAVIES, J., SMITH, S.N., BROWNING, J., DAVIES, M.G., HODSON, M.E., DURHAM, S.R. LI, D., JEFFERY, P.K., SCALLAN, M., BALFOUR, R., EASTMAN, S.J., CHENG, S.H., SMITH, A.E., MEEKER, D., and GEDDES, D.M. (1999). Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: A double-blind placebo-controlled trial. Lancet 353, 947-954.
3. BARGON, J., TRAPNELL, B.C., YOSHIMURA, K., DALEMANS, W., PAVIRANI, A., LECOCQ, J.P., and CRYSTAL, R.G. (1992). Expression of the cystic fibrosis transmembrane conductance regulator gene can be regulated by protein kinase C. J. Biol. Chem. 267, 16056-16060.
4. BESANÇON, F., PRZEWLOCKI, G., BARO, I., HONGRE, A.S., ESCANDE, D., and EDELMAN, A. (1994). Interferon-γ downregulates CFTR gene expression in epithelial cells. Am. J. Physiol. 267, C1398-C1404.
5. BOUCHER, R.C. (1999). Status of gene therapy for cystic fibrosis lung disease. J. Clin. Invest. 103, 441-445.
6. BRADY, K.G., KELLEY, T.J., and DRUMM, M.L. (2001). Examining basal chloride transport using the nasal potential difference response in a murine model. Am. J. Physiol. Lung Cell Mol. Physiol. 281, L1173-L1179.
7. BREUER, W., GLICKSTEIN, H., KARTNER, N., RIORDAN, J.R., AUSIELLO, D.A., and CABANTCHIK, I.Z. (1993). Protein kinase C mediates down-regulation of cystic fibrosis transmembrane conductance regulator levels in epithelial cells. J. Biol. Chem. 268, 13935-13939.
8. CAFFERATA, E.G., GONZALEZ-GUERRICO, A.M., GIORDANO, L., PIVETTA, O.H., and SANTA-COLOMA, T.A. (2000). Interleukin-1β regulates CFTR expression in human intestinal T84 cells. Biochim. Biophys. Acta 1500, 241-248.
9. CAPLEN, N.J., ALTON, E.W., MIDDLETON, P.C., DORIN, J.R., STEVENSON, B.J., GAO, X., DURHAM, S.R., JEFFERY, P.K., HODSON, M.E., COUTELLE, C., HUANG, L., PORTEOUS, D.J., WILLIAMSON, R., and GEDDES, D.M. (1995). Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat. Med. 1, 39-46.
10. CHAFFEE, S., MARY, A., STIEHM, E.R., GIRAULT, D., FISCHER, A., and HERSHFIELD, M.S. (1992). IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Invest. 89, 1643-1651.
11. CHEN, W.Y., BAILEY, E.C., McCUNE, S.L., DONG, J.-Y., and TOWNES, T.M. (1997). Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc. Natl. Acad. Sci. U.S.A. 94, 5798-5803.
12. CHIRMULE, N., XIAO, W., TRUNEH, A., SCHNELL, M.A., HUGHES, J.V., ZOLTICK, P., and WILSON, J.M. (2000). Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol. 74, 2420-2425.
13. CONRAD, C.K., ALLEN, S.S., AFIONE, S.A., REYNOLDS, T.C., BECK, S.E., FEE-MAKI, M., BARRAZZA-ORTIZ, X., ADAMS, R., ASKIN, F.B., CARTER, B.J., GUGGINO, W.B., and FLOTTE, T.R. (1996). Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther. 3, 658-668.
14. COYLE, A.J., ACKERMAN, S.J., and IRVIN, C.G. (1993). Cationic proteins induce airway hyperresponsiveness dependent on charge interactions. Am. Rev. Respir. Dis. 147, 896-900.
15. CRYSTAL, R.G., MCELVANEY, N.G., ROSENFELD, M.A., CHU, C.S., MASTRANGELI, A., HAY, J.G., BRODY, S.L., JAFFE, H.A., EISSA, N.T., and DANEL, C. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8, 42-51.
16. DAVIS, P.B., DRUMM, M., and KONSTAN, M.W. (1996). Cystic fibrosis. Am. J. Respir. Crit. Care Med. 154, 1229-1256.
17. DAVIS, P.B., SCHLUCHTER, M.D., and KONSTAN, M.W. (2004). Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis. Pediatr. Pulmonol. 38, 204-209.
18. DORIN, J.R., PARLEY, R., WEBB, S., SMITH, S.N., FARINI, E., DELANEY, S.J., WAINWRIGHT, B.J., ALTON, E.W., and PORTEOUS, D.J. (1996). A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Ther. 3, 797-801.
19. DRUMM, M.L., POPE, H.A., CLIFF, W.H., ROMMENS, J.M., MARVIN, S.A., TSUI, L.C., COLLINS, F.S., FRIZZELL, R.A., and WILSON, J.M. (1990). Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 62, 1227-1233.
20. FERKOL, T., PELLICENA-PALLE, A., ECKMAN, E., PERALES, J.C., TRZASKA, T., TOSI, M., REDLINE, R., and DAVIS, P.B. (1996). Immunologic responses to gene transfer into mice via the polymeric immunoglobulin receptor. Gene Ther. 8, 669-678.
21. FLOTTE, T.R., ZEITLIN, P.L., REYNOLDS, T.C., HEALD, A.E., PEDERSEN, P., BECK, S., CONRAD, C.K., BRASS-ERNST, L., HUMPHRIES, M., SULLIVAN, K., WETZEL, R., TAYLOR, G., CARTER, B.J., and GUGGINO, W.B. (2003). Phase I trial of intranasal and endobronchial administration of a recombinant adenoassociated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: A two-part clinical study. Hum. Gene Ther. 14, 1079-1088.
22. GILL, D.R., SOUTHERN, K.W., MOFFORD, K.A., SEDDON, T., HUANG, L., SORGI, F., THOMSON, A., MACVINISH, L.J., RATCLIFF, R., BILTON, D., LANE, D.J., LITTLEWOOD, J.M., WEBB, A.K., MIDDLETON, P.G., COLLEDGE, W.H., CUTHBERT, A.W., EVANS, M.J., HIGGINS, C.F., and HYDE, S.C. (1997). A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 4, 199-209.
23. GILL, D.R., SMYTH, S.E., GODDARD, C.A., PRINGLE, I.A., HIGGINS, C.F., COLLEDGE, W.H., and HYDE, S.C. (2001). Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1α promoter. Gene Ther. 8, 1539-1546.
24. GOLDMAN, M.J., YANG, Y., and WILSON, J.M. (1995). Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect. Nat. Genet. 9, 126-131.
25. HARVEY, B.G., LEOPOLD, P.L., HACKETT, N.R., GRASSO, T.M., WILLIAMS, P.M., TUCKER, A.L., KANER, R.J., FERRIS, B., GONDA, I., SWEENEY, T.D., RAMALINGAM, R., KOVESDI, I., SHAK, S., and CRYSTAL, R.G. (1999). Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J. Clin. Invest. 104, 1245-1255.
26. HAY, J.G., MCELVANEY, N.G., HERENA, J., and CRYSTAL, R.G. (1995). Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum. Gene Ther. 6, 1487-1496.
27. HEDA, G.D., TANWANI, M., and MARINO, C.R. (2001). The ΔF508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am. J. Physiol. Cell Physiol. 280, C166-C174.
28. HYDE, S.C., GILL, D.R., HIGGINS, C.F., TREZISE, A.E., MACVINISH, L.J., CUTHBERT, A.W., RATCLIFF, R., EVANS, M.J., and COLLEDGE, W.H. (1993). Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 362, 250-255.
29. JOHNSON, L.G., OLSEN, J.C., SARKADI, B., MOORE, K.L., SWANSTROM, R., and BOUCHER, R.C. (1992). Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat. Genet. 2, 21-25.
30. JOHNSON, L.G., BOYLES, S.E., WILSON, J., and BOUCHER, R.C. (1995). Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J. Clin. Invest. 95, 1377-1382.
31. JOOSS, K., and CHIRMULE, N. (2003). Immunity to adenovirus and adeno-associated viral vectors: Implication for gene therapy. Gene Ther. 10, 955-963.
32. KEREM, B., ROMMENS, J.M., BUCHANAN, J.A., MARKIEWICZ, D., COX, T.K., CHAKRAVARTI, A., BUCHWALD, M., and TSUI, L.-C. (1989). Identification of the cystic fibrosis gene: Genetic analysis. Science 245, 1073-1080.
33. KERSCHMANN, R,. ZIADY, A., PAYNE, J.M., GEDEON, C., MUHAMMAD, O., KOWALCZYK, T.H., PASUMARTHY, M.K., HYATT, S., MOEN, R.C., and COOPER, M.J. (2001). Three-dimensional imaging of EGFP expression in mouse lung using compacted DNA nanoparticles. Mol. Ther. 3, S404.
34. KNOWLES, M.R., HOHNEKER, K.W., ZHOU, Z., OLSEN, J.C., NOAH, T.L., HU, P.C., LEIGH, M.W., ENGELHARDT, J.F., EDWARDS, L.J., JONES, K.R., GROSSMAN, M., WILSON, J.M., JOHNSON, L.G., and BOUCHER, R.C. (1995a). A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333, 823-831.
35. KNOWLES, M.R., PARADISO, A.M., and BOUCHER, R.C. (1995b). In vivo nasal potential difference: Techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum. Gene Ther. 6, 445-455.
36. - concentration. EMBO Rep. 2, 1047-1051.
37. KONSTAN, M.W., and DAVIS, P.B. (2002). Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv. Drug Deliv. Rev. 54, 1409-1423.
38. KOWALCZYK, T.H., GEDEON, C.R., OETTE, S.M., MUHAMMAD, O., HYATT, S.L., PEISCHL, A.R., FINK, T.L., KLEPCYK, P.J., MOEN, R.C., COOPER, M.J., and GILL, D.R. (2003). Ubiquitin promoter generates prolonged high level gene expression following intrapulmonary administration of compacted DNA nanoparticles. Mol. Ther. 7, S324.
39. KUBE, D., and DAVIS, P.B. (2003). Intracellular trafficking of non-targeted stabilized molecular conjugates in human airway epithelia cells. Mol. Ther. 7, S371.
40. LECHARDEUR, D., SOHN, K.J., HAARDT, M., JOSHI, P.B., MONCK, M., GRAHAM, R.W., BEATTY, B., SQUIRE, J., O'BRODUVICH, H., and LUKACS, G.L. (1999). Metabolic instability of plasmid DNA in the cytosol: A potential barrier to gene transfer. Gene Ther. 6, 482-497.
41. LIU, G., LI, D., PASUMARTHY, M.K., KOWALCZYK, T.H., GEDEON, C., HYATT, S., PAYNE, J.M., MILLER, T.J., BRUNOVSKIS, P., MOEN, R.C., HANSON, R.W., and COOPER, M.J. (2003). Nanoparticles of compacted DNA transfect post-mitotic cells. J. Biol. Chem. 278, 32578-32586.
42. LUKACS, G.L., CHANG, X.B., BEAR, C., KARTNER, N., MOHAMED, A., RIORDAN, J.R., and GRINSTEIN, S. (1993). The ΔF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane: Determination of functional half-lives on transfected cells. J. Biol. Chem. 268, 21592-21598.
43. + absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 10, 487-493.
44. McELVANEY, N.G., and CRYSTAL, R.G. (1995). IL-6 release and airway administration of human CFTR cDNA adenovirus vector. Nat. Med. 1, 182-184.
45. MIDDLETON, P.C., GEDDES, D.M., and ALTON, E.W. (1994). Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur. Respir. J. 7, 2050-2056.
46. MOSS, R.B., RODMAN, D., SPENCER, L.T., AITKEN, M.L., ZEITLIN, P.L., WALTZ, D., MILLA, C., BRODY, A.S., CLANCY, J.P., RAMSEY, B., HAMBLETT, N., and HEALD, A.E. (2004). Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: A multicenter, double-blind, placebo-controlled trial. Chest 125, 509-521.
47. NAKAMURA, H., YOSHIMURA, K., BAJOCCHI, G., TRAPNELL, B.C., PAVIRANI, A., and CRYSTAL, R.G. (1992). Tumor necrosis factor modulation of expression of the cystic fibrosis transmembrane conductance regulator gene. FEBS Lett. 314, 366-370.
48. NOONE, P.G., HOHNEKER, K.W., ZHOU, Z., JOHNSON, L.G., FOY, C., GIPSON, C., JONES, K., NOAH, T.L., LEIGH, M.W., SCHWARTZBACH, C., EFTHIMIOU, J., PEARLMAN, R., BOUCHER, R.C., and KNOWLES, M.R. (2000). Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol. Ther. 1, 105-114.
49. OETTE, S.M., GEDEON, C.R., KOWALCZYK, T.H., FINK, T.L., HYATT, S.L., MOEN, R.C., and COOPER, M.J. (2004). Aerosols of compacted DNA nanoparticles retain structural integrity and biological activity. Mol. Ther. 9, S190.
50. PLANK, C., MECHTLER, K., SZOKA, P.C., and WAGNER, E. (1996). Activation of the complement system by synthetic DNA complexes: A potential barrier for intravenous gene delivery. Hum. Gene Ther. 7, 1437-1446.
51. 2+-sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids. J. Gene Med. 3, 153-164.
52. PORTEOUS, D.J., DORIN, J.R., McLACHLAN, G., DAVIDSON-SMITH, H., DAVIDSON, H., STEVENSON, B.J., CAROTHERS, A.D., WALLACE, W.A., MORALEE, S., HOENES, C., KALLMEYER, G., MICHAELIS, U., NAUJOKS, K., HO, L.P., SAMWAYS, J.M., IMRIE, M., GREENING, A.P., and INNES, J.A. (1997). Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 4, 210-218.
53. PROSCH, S., STEIN, J., STAAK, K., LIEBENTHAL, C., VOLK, H,-D., and KRUGER, D.H. (1996). Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol. Chem. Hoppe-Seyler 377, 195-201.
54. QIN, L., DING, Y., PAHUD, D.R., CHANG, E., IMPERIALE, M.J., and BROMBERG, J.S. (1997). Promoter attenuation in gene therapy: Interferon-γ and tumor necrosis factor-α inhibit transgene expression. Hum. Gene Ther. 8, 2019-2029.
55. RAMSEY, B.W. (1996). Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med. 335, 179-188.
56. RIORDAN, J.R., ROMMENS, J.M., KEREM, B., ALON, N., ROZMAHEL, R., GRZELCZAK, Z., ZIELENSKI, J., LOK, S., PLAVSIC, N., CHOU, J.L., DRUMM, M.L., IANNUZZI, M.C., COLLINS, F.S., and TSUI, L.-C. (1989). Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 245, 1066-1073.
57. ROMMENS, J.M., IANNUZZI, M.C., KEREM, B., DRUMM, M.L., MELMER, G., DEAN, M., ROZMAHEL, R., COLE, J.L., KENNEDY, D., HIDAKA, N., ZSIGA, M., BUCHWALD, M., RIORDAN, J.R., TSUI, L.-C., and COLLINS, F.S. (1989). Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science 245, 1059-1065.
58. RUIZ, F.E., CLANCY, J.P., PERRICONE, M.A., BEBOK, Z., HONG, J.S., CHENG, S.H., MEEKER, D.P., YOUNG, K.R., SCHOUMACHER, R.A., WEATHERLY, M.R., WING, L., MORRIS, J.E., SINDEL, L., ROSENBERG, M., van GINKEL, F.W., McGHEE, J.R., KELLY, D., LYRENE, R.K., and SORSCHER, E.J. (2001). A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum. Gene Ther. 12, 751-761.
59. SCHEULE, R.K., ST. GEORGE, J.A., BAGLEY, R.G., MARSHALL, J., KAPLAN, J.M., AKITA, G.Y., WANG, K.X., LEE, E.R., HARRIS, D.J., JIANG, C., YEW, N.S., SMITH, A.E., and CHENG, S.H. (1997). Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum. Gene Ther. 8, 689-707.
60. SCHWARTZ, D.A., QUINN, T.J., THORNE, P.S., SAYEED, S., YI, A.K., and KRIEG, A.M. (1997). CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J. Clin. Invest. 100, 68-73.
61. STANDAERT, T.A., BOITANO, L., EMERSON, J., MILGRAM, L.J.H., KONSTAN, M.W., HUNTER, J., BERCLAZ, P.-Y., BRASS, L., ZEITLIN, P.L., HAMMOND, K., DAVIES, Z., FOY, C., NOONE, P.C., and KNOWLES, M.R. (2004). Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials. Pediatr. Pulmonol. 37, 385-392.
62. SUAUD, L., LI, J., JIANG, Q., RUBENSTEIN, R.C., and KLEYMAN, T.R. (2002). Genistein restores functional interactions between AFSOS-CFTR and ENaC in Xenopus oocytes. J. Biol. Chem. 277, 8928-8933.
63. SUN, J.Y., ANAND-JAWA, V., CHATTERJEE, S., and WONG, K.K. (2003). Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther. 10, 964-976.
64. TRAPNELL, B.C., CHU, C.S., PAAKKO, P.K., BANKS, T.C., YOSHIMURA, K., FERRANS, V.J., CHERNICK, M.S., and CRYSTAL, R.G. (1991). Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis. Proc. Natl. Acad. Sci. U.S.A. 88, 6565-6569.
65. TSUTSUMI, Y., ONDA, M., NAGATA, S., LEE, B., KREITMAN, R.J., and PASTAN, I. (2000). Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-' PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA. 97, 8548-8553.
66. WAGNER, J.A., REYNOLDS, T., MORAN, M.L., MOSS, R.B., WINE, J.J., FLOTTE, T.R., and GARDNER, P. (1998). Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 351, 1702-1703.
67. WAGNER, J.A., MESSNER, A.H., MORAN, M.L., DAIFUKU, R., KOUYAMA, K., DESCH, J.K., MANLEY, S., NORBASH, A.M., CONRAD, C.K., FRIBORG, S., REYNOLDS, T., GUGGINO, W.B., MOSS, R.B., CARTER, B.J., WINE, J.J., FLOTTE, T.R., and GARDNER, P. (1999). Safety and biological efficacy of an adenoassociated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 109, 266-274.
68. WAGNER, J.A., NEPOMUCENO, I.B., MESSNER, A.H., MORAN, M.L., BATSON, E.P., DIMICELI, S., BROWN, B.W., DESCH, J.K., NORBASH, A.M., CONRAD, C.K., GUGGINO, W.B., FLOTTE, T.R., WINE, J.J., CARTER, B.J., REYNOLDS, T.C., MOSS, R.B., and GARDNER, P. (2002). A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 13, 1349-1359.
69. WANG, Q.C., PAI, L.H., DEBINSKI, W., FITZGERALD, D.J., and PASTAN, I. (1993). Polyethylene glycol-modified chimeric toxin composed of transforming growth factor a and Pseudomonas exotoxin. Cancer Res. 53, 4588-4594.
70. WELSH, M.J. (1999). Gene transfer for cystic fibrosis. J. Clin. Invest. 104, 1265-1266.
71. WELSH, M.J., TSUI, L.-C., BOAT, T.F., and BEAUDET, A.L. (1995). Cystic fibrosis. In The Metabolic and Molecular Basis of Inherited Disease, 7th ed., Vol. 3. C. Scriver, A.L. Beaudet, and D. Valle, eds. (McGraw Hill, New York) pp. 3799-3876.
72. WILMOTT, R.W., AMIN, R.S., PEREZ, C.R., WERT, S.E., KELLER, G., BOIVIN, G.P., HIRSCH, R., DE INOCENCIO, J., LU, P., REISING, S.F., YEI, S., WHITSETT, J.A., and TRAPNELL, B.C. (1996). Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates. Hum. Gene Ther. 7, 301-318.
73. YEW, N.S., WANG, K.X., PRZYBYLSKA, M., BAGLEY, R.G., STEDMAN, M., MARSHALL, J., SCHEULE, R.K., and CHENG, S.H. (1999). Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum. Gene Ther. 10, 223-234.
74. ZABNER, J., RAMSEY, B.W., MEEKER, D.P., AITKEN, M.L., BALFOUR, R.P., GIBSON, R.L., LAUNSPACH, J., MOSCICKI, R.A., RICHARDS, S.M., STANDAERT, T.A., WILLIAMS-WARREN, J., WADSWORTH, S.C., SMITH, A.E., and WELSH, M.J. (1996). Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J. Clin. Invest. 97, 1504-1511.
75. ZABNER, J., CHENG, S.H., MEEKER, D., LAUNSPACH, J., BALFOUR, R., PERRICONE, M.A., MORRIS, J.E., MARSHALL, J., FASBENDER, A., SMITH, A.E., and WELSH, M.J. (1997). Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J. Clin. Invest. 100, 1529-1537.
76. ZIADY, A.G., OETTE, S., GEDEON, C., PAYNE, J.M., HYATT, S., MUHAMMAD, O., KOWALCZYK, T.H., PASUMARTHY, M.K., COOPER, M.J., MOEN, R.C., and DAVIS, P.B. (2002). Stabilized PLASmin® complexes deliver exogenous genes to the nasal epithelia of cystic fibrosis (CF) knockout mice and confer partial physiological correction of CFTR-mediated chloride transport. Mol. Ther. 5, S435.
77. ZIADY, A.G., GEDEON, C.R., MILLER, T., QUAN, W., PAYNE, J.M., HYATT, S.L., FINK, T.L., MUHAMMAD, O., OETTE, S., KOWALCZYK, T., PASUMARTHY, M.K., MOEN, R.C., COOPER, M.J., and DAVIS, P.B. (2003a). Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol. Ther. 8, 936-947.
78. ZIADY, A.G., GEDEON, C.R., MUHAMMAD, O., OETTE, S.M., FINK, T.L., QUAN, W., KOWALCZYK, T.H., HYATT, S.L., PEISCHL, A., SENG, J.E., MOEN, R.C., COOPER, M.J., and DAVIS, P.B. (2003b). Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol. Ther. 8, 948-956.
79. ZIADY, A.G., KIM, J., COLLA, J., and DAVIS, P.B. (2004). Defining strategies to extend duration of gene expression from targeted compacted DNA vectors. Gene Ther. 11, 1378-1390.
80. ZUCKERMAN, J.B., ROBINSON, C.B., MCCOY, K.S., SHELL, R., SFERRA, TJ., CHIRMULE, N., MAGOSIN, S.A., PROPERT, K.J., BROWN-PARR, E.C., HUGHES, J.V., TAZELAAR, J., BAKER, C., GOLDMAN, M.J., and WILSON, J.M. (1999). A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum. Gene Ther. 10, 2973-2985.